New combo therapy shows promise for aggressive breast cancer
NCT ID NCT03368729
First seen Jan 28, 2026 · Last updated May 20, 2026 · Updated 19 times
Summary
This study tests a combination of two drugs—niraparib and trastuzumab—in people with metastatic HER2-positive breast cancer, an aggressive form of the disease. The goal is to see if the combination is safe and can shrink tumors or slow cancer growth. About 46 women with advanced cancer that has spread will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Montefiore
The Bronx, New York, 10461, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27599, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Washington-
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.